A unique opportunity exists to contribute to a study shaping policy and clinical practice around the treatment of pain in Australia. POPPY II is a retrospective population-based cohort study of approximately 3.5 million people prescribed opioids in NSW between 2002 and 2018. This world-first study involves a cross-jurisdictional linkage of ten datasets, including data on pharmaceutical claims, health service utilisation (including primary care access, hospitalisations and emergency department presentations) and mortality.
The Biostatistician will be responsible for supporting the project team in achieving the aims of the study. This will involve designing, planning and analyzing a range of pharmaco/epidemiological studies using linked health data (for approximately 3.5 million people), including descriptive studies relating to different opioid exposures and outcomes, as well as more complex study designs to establish the potential association between differing levels of opioid exposure and a range of health-related outcomes.